The average EPS estimate for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for the three-month period quarter ended 2016-09-30 stands at $0.18.
The EPS estimates for the stock 7 days ago was$0.18 and for 30 days ago it was $0.18. For 60 and 90 days ago, the stock had EPS estimates of $0.18 and $0.18 respectively. If you look at the latest 7 days and the prior 7 days, if you find that the stock’s EPS estimate changed 0%.
The last 7 days saw 0 upwards EPS revisions on the stock compared to 0 downward EPS revisions over the same period. In the last 30 and 60 days, the number of upward EPS estimates revisions were 0 and 0, respectively. That compared with upward EPS estimates revisions of 2 and 2 for the last 90 and 120 days, respectively.
As for the last 18 days, the number of upward and downward EPS revisions on the stock were 0 and 2 respectively.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) posted actual EPS of $0.08 on 2016-05-03 for the quarter ended 1. That compared with the average EPS estimate for the quarter of $0.18, based on a total of 5 EPS estimates on the stock.
As such, the EPS surprise in dollar terms per share was $0 and percentage surprise was 0%. That works out to standard deviation of 0.02 if you take into account all the EPS estimates before the actual EPS report.
Quarterly Sales Estimates
The mean sales estimate for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) for the fiscal year 2016 is $59.615 while the median sales estimate is $59.155. The mean and median sales estimates are worked out based on the accounts of 4 analysts covering the stock for the cited fiscal year.
The highest sales estimate for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is $62.7 while the lowest sales estimate is $57.45. That works out to standard deviation of 2.373%.
In the past week, 4 analysts have raised their sales estimates on the stock while 4 analysts have trimmed their sales estimates. That works out a percentage change in mean sales estimate of 0% from the past week.
In the last one month, 4 analysts have increased their sales estimates on the stock while 4 analysts have reduced their sales estimates. With that, you find that the percentage change in mean sales estimate since one month ago stands at -0.459%.
Since three months ago, 4 analysts have raised their sales estimates for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and 4 have lowered their sales estimates for the stock. Therefore, the percentage change in mean sales estimate for the stock from the last three months is -0.778%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...